Search results
Results from the WOW.Com Content Network
HIV Drug Resistance Database, also known as Stanford HIV RT and Protease Sequence Database, is a database at Stanford University that tracks 93 common mutations of HIV.It has been recompiled in 2008 listing 93 common mutations, after its initial mutation compilation in 2007 of 80 mutations.
The Stanford HIV RT and Protease Sequence Database (also called the “HIV Drug Resistance Database”) was formed in 1998 with HIV reverse transcriptase and protease sequences from persons with well-characterized antiretroviral treatment histories, and is publicly available to query resistance mutations and genotype-treatment, genotype ...
HIV Resistance Response Database Initiative (RDI) was formed in 2002 to use artificial intelligence (AI) to predict how patients will respond to HIV drugs using data from more 250,000 patients from around 50 countries around the world. The RDI used its models to power its HIV Treatment Response Prediction System (HIV-TRePS).
The Stanford HIV Drug Resistance Database and the International AIDS Society publish lists of the most important of these; first year listing 80 common mutations, and the latest year 93 common mutations, and made available through the Stanford HIV RT and Protease Sequence Database. [citation needed]
The development of effective anti-HIV drugs is difficult due to wide variations in nucleotide and amino acid sequences. The perfect anti-HIV drug chemical should be effective against drug resistance mutation. Understanding the target RT enzyme and its structure, mechanism of drug action and the consequence of drug resistance mutations provide ...
As of July 2017, the WHO is implementing the Global Action Plan on HIV drug resistance 2017–2021. It is a 5-year initiative intended to help countries around the world manage HIV drug resistance. [19] Among treatment methods, the World Health Organization acknowledges the importance of successful first-line treatments. [18]
The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), formerly the National Center for HIV, STD, and TB Prevention (NCHSTP) is a part of the Centers for Disease Control and Prevention and is responsible for public health surveillance, prevention research, and programs to prevent and control human immunodeficiency virus (HIV) infection and acquired ...
One approach to minimizing the development of drug-resistance in HIV is to administer a combination of drugs which inhibit several key aspects of the HIV replication cycle simultaneously, rather than one drug at a time. Other drug therapy targets include reverse transcriptase, virus attachment, membrane fusion, cDNA integration and virion assembly.